Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
1. Mainz Biomed will participate in GARPS annual meeting on November 14-15, 2025.
2. The conference focuses on gastroenterology, enhancing industry relationships and knowledge exchange.
3. Mainz Biomed will showcase its flagship product, ColoAlert®, at the event.
4. ColoAlert® aids in early colorectal cancer detection, crucial for market positioning.
5. The conference promotes collaboration opportunities with healthcare professionals.
Participation in GARPS may enhance visibility and partnerships, potentially increasing sales of ColoAlert®. Historical precedents show similar events positively impacting stock after networking and new collaborations.
How important is it?
The article highlights a key event for Mainz Biomed, suggesting potential growth opportunities which are critical for stock performance.
Why Short Term?
The effects from this conference will likely materialize shortly after, affecting partnerships and product awareness directly in the market.
BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) taking place from 14–15 November, 2025, in Bad Kreuznach, Germany.
The annual GARPS conference brings together clinical and scientific expertise from across the Rhineland-Palatinate region, serving as an important platform for knowledge exchange in the fields of gastroenterology and hepatology. This form of regional congress promotes valuable dialogue between universities, hospitals, private practices, and representatives of the research and diagnostics industry.
Mainz Biomed will use the opportunity to further strengthen relationships with key opinion leaders in gastroenterology, exchange insights on the future of cancer prevention, and present its current flagship product, ColoAlert®, and further upcoming diagnostic solutions designed to enhance early detection of colorectal and other cancers.
Attendees are invited to visit the booth to learn more about the critical significance of early colorectal cancer detection and to explore potential collaborations with physicians and how to offer ColoAlert to their patients.
About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries MC Services AG Maximilian Schur / Simone Neeten +49 211 529252 20 mainzbiomed@mc-services.eu
Forward-Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
